Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2017 Dec 3

PMID 29196934

Citations 1

Authors

Marianna Criscuolo

Luana Fianchi

Patrizia Chiusolo

Sabrina Giammarco

Andrea Bacigalupo

Livio Pagano

Affiliations

Soon will be listed here.

Citing Articles

Mycosis Fungoides: Analysis of Ophthalmologic Findings in a Series of Cases.

Colossi C, Mondadori J, Barreto P, Valenca F, Duquia R, Vilela M Case Rep Dermatol Med. 2019; 2019:2380598.

PMID: 30805223 PMC: 6360538. DOI: 10.1155/2019/2380598.

References

Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R . European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer. 2017; 77:57-74. DOI: 10.1016/j.ejca.2017.02.027. View

Koga Y, Takada H, Suminoe A, Ohga S, Hara T . Successful treatment of non-Hodgkin's lymphoma using R-CHOP in a patient with Wiskott-Aldrich syndrome followed by a reduced-intensity stem cell transplant. Pediatr Transplant. 2014; 18(6):E208-11. DOI: 10.1111/petr.12297. View

Dummer R, Quaglino P, Becker J, Hasan B, Karrasch M, Whittaker S . Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012; 30(33):4091-7. DOI: 10.1200/JCO.2011.39.8065. View

Criscuolo M, Fianchi L, Voso M, Pagano L . Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin. Br J Haematol. 2014; 168(5):617. DOI: 10.1111/bjh.13220. View

Tavil B, Erdem A, Azik F, Isik P, Metin A, Emir S . Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma. Pediatr Transplant. 2013; 17(6):E146-8. DOI: 10.1111/petr.12114. View

Shcherbina A, Candotti F, Rosen F, Remold-ODonnell E . High incidence of lymphomas in a subgroup of Wiskott-Aldrich syndrome patients. Br J Haematol. 2003; 121(3):529-30. DOI: 10.1046/j.1365-2141.2003.04310.x. View

Lechowicz M, Lazarus H, Carreras J, Laport G, Cutler C, Wiernik P . Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014; 49(11):1360-5. PMC: 4221526. DOI: 10.1038/bmt.2014.161. View

Jin Y, Mazza C, Christie J, Giliani S, Fiorini M, Mella P . Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004; 104(13):4010-9. DOI: 10.1182/blood-2003-05-1592. View

Chen X, Soma L, Fromm J . Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther. 2014; 7:45-56. PMC: 3872218. DOI: 10.2147/OTT.S39107. View

10.

Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs H . Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood. 2011; 118(6):1675-84. PMC: 3156052. DOI: 10.1182/blood-2010-11-319376. View

11.

Duvic M, Tetzlaff M, Gangar P, Clos A, Sui D, Talpur R . Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015; 33(32):3759-65. PMC: 4737859. DOI: 10.1200/JCO.2014.60.3787. View